

URGENT FIELD SAFETY NOTICE

Product	Version	Part Number
Kaluza C Software	1.0*, 1.1.1, 1.1.2	C10574, C10575, C10576, C10577, C10578, C10579, C10580, C10581, C21166

Attention Beckman Coulter Customer,

Beckman Coulter is initiating a field safety corrective action for the product listed above. This letter contains important information that needs your immediate attention.

ISSUE:	Beckman Coulter has discovered software anomalies in Kaluza C that may lead to the generation of erroneous results.
ISSUE #1:	Transmission of erroneous results to the Laboratory Information System (LIS) may occur any time a gate has been setup for LIS transmission and one or more gates in the data plot has been deleted (viewed as a Gate in the Select Statistics window and Value (result) for LIS transmission in the LIS Preview window). This issue applies to any computer that uses Kaluza C Software and is connected to a LIS.
ISSUE #2:	<p>The autofluorescence values Kaluza C loads from the listmode (LMD) file do not match the values set in the Advanced Compensation Module of Navios or Navios EX.</p> <p>This issue occurs when all the following 3 conditions are met at the same time:</p> <ul style="list-style-type: none"> • Kaluza loads an LMD file generated using the Advanced Compensation module. • The acquisition protocol uses a PEAK or TOF parameter in the third position. • The LMD file contains the @AUTOFL20 keyword and the keyword value is not empty. <p>* Kaluza C Version 1.0 is not impacted by this issue.</p>
IMPACT #1	<p>In a worst-case scenario:</p> <ul style="list-style-type: none"> • Erroneous results could cause a delay in initiating antiretroviral therapy and anti-opportunistic infection preventive treatments, with attendant complications (e.g. opportunistic infections) and disease progression for CD4+ enumeration panel. • For patient with hematologic malignancy, delay or loss of opportunity for planned high dose chemotherapy with rescue stem cell transplant may result in progression of malignancy and related serious complications and/or failure to continue to be a candidate for

	<p>high dose chemotherapy for cure or remission with stem cell “rescue”. For stem cell mobilization, placing patient (for autologous transplantation) and healthy matched donor (allogeneic transplantation) at unnecessary risks of repeat cytokine pulse, (which includes risk of splenic rupture), and all risks of high blood volume apheresis collection.</p> <ul style="list-style-type: none"> • Misclassification or misdiagnosis of hematolymphoid malignancy leading to additional testing and/or re-draw of blood or tissue sample. In a worst-case scenario, there is possible delay in appropriate treatment or initiation of inappropriate treatment with attendant complications. • Transfusion of blood component may be inaccurately labeled as “Leukocytes Reduced” resulting in possible permanent alloimmunization, causing delay or inability of patient to tolerate future urgent or elective blood product transfusion. CMV infection may also occur. In immunocompromised persons, pregnant women, and infants, CMV infection can produce permanent injury.
IMPACT #2	<p>In a worst-case scenario:</p> <ul style="list-style-type: none"> • Erroneous results could cause a delay in initiating antiretroviral therapy and anti-opportunistic infection preventive treatment, with attendant complications (e.g. opportunistic infections) and disease progression for CD4+ enumeration panel. • Misclassification or misdiagnosis of hematolymphoid malignancy or lymphoproliferative disorder, leading to additional testing and/or re-draw of blood or tissue sample. There is possible delay in appropriate treatment or initiation of inappropriate treatment with attendant complications.
ACTION #1:	<p>If you are using a LIS:</p> <ul style="list-style-type: none"> • Review the values in the LIS Preview window for each patient and verify that they correspond to the Kaluza C data plot statistics. • If you see erroneous results, remove the incorrect statistic from the LIS Preview window. • Update the LIS export to include the desired gate statistic following the Kaluza C IFU instructions (Exporting Data to the LIS). Save changes. • Verify all LIS Preview window results and transmit to the LIS. • Consult with your Medical Director to determine if a retrospective review of results is warranted. • Report any erroneous results to Beckman Coulter.
ACTION #2:	<p>If you are using Kaluza C with the Advanced Compensation Module of Navios or Navios EX:</p> <ul style="list-style-type: none"> • Review the statistical results derived from measurements of fluorescence intensity.



	<ul style="list-style-type: none">• If erroneous results are observed, manually adjust autofluorescence values, re-analyze the data using the adjusted autofluorescence values and verify that the correct values are generated.• Consult with your Medical Director to determine if a retrospective review of results is warranted.• Report any erroneous results to Beckman Coulter.
RESOLUTION:	Beckman Coulter will provide an update to Kaluza C Software to resolve the issue.

The national competent authority has been informed of this field safety corrective action.

Please share this information with your laboratory staff and retain this notification as part of your laboratory Quality System documentation. If you have forwarded any of the affected product(s) listed above to another laboratory, please provide them a copy of this letter.


Please complete and return the enclosed Response Form within 10 days so we are assured you have received this important communication.

If you have any questions regarding this notice, please contact:

- From our website: <http://www.beckman.com>
- By phone: call 800-369-0333 in the United States and Canada
- Outside the United States and Canada, contact your local Beckman Coulter representative.

We apologize for the inconvenience that this caused your laboratory.

Sincerely,



Enclosure: Response Form

Beckman Coulter, the stylized logo and the Beckman Coulter product and service names mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.